Netherlands Cancer Institute
Latest From Netherlands Cancer Institute
Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.
With Third Rock partners in executive roles, a personalized vaccine will go into clinical development in 2016, but Neon also plans to develop a personalized T-cell therapy and off-the-shelf vaccines and T-cell therapies based on groundbreaking neoantigen biology.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.